An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.

Book profits on rallies as Nifty is witnessing a ‘Bearish Butterfly’ on the charts

Jay Purohit, Technical & Derivatives Analyst at Centrum Broking Limited, says short-term traders are advised to book some profit at current levels.

Australia biz expanded; rebounded strongly in India & EMs: Strides Shasun

In an interview to CNBC-TV18, Shashank Sinha, Managing Director of Strides Shasun spoke about the results and his outlook for the company.

Will be vertically integrated formulation company: Strides Shasun

In an interview to CNBC-TV18, Shashank Sinha, MD & GROUP CEO of Strides Shasun spoke about the latest happenings in his company and sector.

Remain bullish about performance overall in FY18: Strides Shasun

Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company. There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.

Sequent Scientific gets CCI approval for Scheme of Arrangement

Competition Commission of India (CCI) approves Scheme of Arrangement between Strides Shasun, Sequent Scientific and Solara Active Pharma Sciences. In an interview to CNBC-TV18, Manish Gupta, CEO of Sequent Scientific spoke about the same.

Border tax counter productive for US, may never happen: Strides

Going forward, the pharma company is going to to focus on its B2C business and the high cash generating verticals, he says.

Regulatory claims on Agila settled, says Strides Shasun

There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.

Q2 has been a comeback quarter for us in EMs: Stides Shasun

In an interview to CNBC-TV18, Shashank Sinha, Group CEO of Strides Shasun spoke about the results and his outlook for the company.

Data integrity issues hamper relations with regulators: Strides

In an interview to CNBC-TV18, Arun Kumar, Founder & MD of Strides Shasun says that the pharma industry lacks trust now as more and more issues with regulators come to light.

API biz turnaround likely in 6-8 months: Strides Shasun

In an interview to CNBC-TV18, Arun Kumar, Executive VC and MD of Strides Shasun said the company may sell off its API unit after enhancing its value.

See margin growing, Australian biz picking up: Strides Shasun

Third quarter performance was hit due to floods in Chennai but there has been a strong pullback in the last quarter, he said, adding growth in business from regulated markets like Australia and the US have helped, said Arun Kumar, Executive VC & MD at Strides Shasun.

Aim to grow biz at 20-25% CAGR: Strides Shasun

The growth trajectory is very strong going forward and the company has all the necessary engines to grow the business at 20-25 percent CAGR, said Arun Kumar, MD, Strides Shasun.

Hope to complete merger formalities by October end: Shasun

Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.

Strides Arcolab to buy Aspen's generic biz in Australia

The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.

Special dividend of Rs 500/share to cost us $525mn: Strides

Strides Arcolab has a fairly strong organic growth strategy in place at the moment, says Group CEO & VC Arun Kumar.

Ailing pharma sector needs uniform drug standards: Ranbaxy

Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

Strides Arcolab arm in JV with Pfenex for biosimilar drugs

Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

Strides Arcolab bets on Agila to drive growth in FY13

Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.

Sale proceeds to help cut debt, repay FCCB: Strides Arcolab

Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.

Strides Arcolab eyes 30-35% growth in current year

In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

Strides, Pfizer to deal post US FDA nod on Oncology unit

Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

Stride Arcolab targets Rs 2200cr revenue in 2011

Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”

Strides Arcolab expects more approvals from US FDA soon

In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.

Business to grow Rs 1000cr in FY11: Stride Arcolab

Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.